Literature DB >> 28267115

POOLED ESTIMATES OF INCIDENCE OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS WITH AND WITHOUT TOPICAL ANTIBIOTIC PROPHYLAXIS.

Michele Reibaldi1, Alfredo Pulvirenti2, Teresio Avitabile1, Vincenza Bonfiglio1, Andrea Russo1, Cesare Mariotti3, Claudio Bucolo4, Rodolfo Mastropasqua5, Guglielmo Parisi1, Antonio Longo1.   

Abstract

PURPOSE: To assess the effect of topical antibiotic prophylaxis on postoperative endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
METHODS: A systematic literature search was performed from inception to March 2016 using PubMed, Medline, Web of Science, Embase, and the Cochrane Library, to identify articles that reported cases of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. We used a pooled analysis to estimate the incidence of cases of endophthalmitis who developed after injections performed with and without topical antibiotic prophylaxis. We used regression analysis to explore the effects of study characteristics on heterogeneity.
RESULTS: From our search of electronic databases, we identified and screened 4,561 unique records. We judged 60 articles to have reported findings for cohorts of patients who met our inclusion criteria, (12 arms of randomized clinical trials, 11 prospective cohort studies, and 37 retrospective cohort studies), which included 244 cases of endophthalmitis and 639,391 intravitreal injections of anti-vascular endothelial growth factor agents. The final pooled estimate endophthalmitis proportions were 9/10,000 (95% confidence interval, 7/10,000-12/10,000) in the antibiotic-treated group and 3/10,000 (95% confidence interval, 2/10,000-5/10,000) in the untreated group. The estimated incidence of endophthalmitis with topical antibiotic prophylaxis was approximated three times the incidence without prophylaxis. Random effects regression showed that none of the study characteristics significantly affected the effect size in either group.
CONCLUSION: Topical antibiotic after intravitreal injection of anti-vascular endothelial growth factor agents is associated with a higher risk of endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28267115     DOI: 10.1097/IAE.0000000000001583

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  15 in total

1.  Antibiotic prophylaxis for preventing endophthalmitis after intravitreal injection: a systematic review.

Authors:  Francesca Menchini; Giacomo Toneatto; Alba Miele; Simone Donati; Paolo Lanzetta; Gianni Virgili
Journal:  Eye (Lond)       Date:  2018-06-11       Impact factor: 3.775

2.  Endophthalmitis after intravitreal injections versus cataract surgery: a 15-year cohort.

Authors:  Nimrod Dar; Shani Pillar; Asaf Friehmann; Avner Belkin; Shay Ofir
Journal:  Int Ophthalmol       Date:  2019-08-14       Impact factor: 2.031

3.  Design, construction and in vivo functional assessment of a hinge truncated sFLT01.

Authors:  Fahimeh Zakeri; Hamid Latifi-Navid; Zahra-Soheila Soheili; Mehdi Sadeghi; Seyed Shahriar Arab; Shahram Samiei; Ehsan Ranaei Pirmardan; Sepideh Taghizadeh; Hamid Ahmadieh; Ali Hafezi-Moghadam
Journal:  Gene Ther       Date:  2022-09-16       Impact factor: 4.184

4.  Culture-Proven Endophthalmitis After Intravitreal Injection: A 10-Year Analysis.

Authors:  Joseph M Simonett; Austin Igelman; Stanford C Taylor; J Peter Campbell; Thomas S Hwang; Phoebe Lin; Andreas K Lauer; Christina J Flaxel
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2019-01-01       Impact factor: 1.300

5.  The effects of anti-VEGF and kinin B1 receptor blockade on retinal inflammation in laser-induced choroidal neovascularization.

Authors:  Soumaya Hachana; Olivier Fontaine; Przemyslaw Sapieha; Mark Lesk; Réjean Couture; Elvire Vaucher
Journal:  Br J Pharmacol       Date:  2020-02-04       Impact factor: 8.739

Review 6.  Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections.

Authors:  P Et Lau; K S Jenkins; C J Layton
Journal:  J Ophthalmol       Date:  2018-07-24       Impact factor: 1.909

7.  The short-term effects of intravitreal aflibercept injections and dexamethasone implant on ocular hemodynamics in retinal vein occlusions.

Authors:  Emine Ciloglu; Ayse Yıldırım Celikdemir
Journal:  Ther Clin Risk Manag       Date:  2019-07-04       Impact factor: 2.423

8.  Incidence of endophthalmitis after intravitreal injection of an anti-VEGF agent with or without topical antibiotics.

Authors:  Masakazu Morioka; Yoshihiro Takamura; Kazuki Nagai; Shigeo Yoshida; Junya Mori; Masaru Takeuchi; Tomoko Sawada; Kumiko Sone; Hisashi Fukuyama; Sentaro Kusuhara; Tsutomu Yasukawa; Tomoya Murakami; Hitoshi Tabuchi; Daisuke Nagasato; Takao Hirano; Tetsuo Ueda; Tatsuya Jujo; Hirofumi Sasajima; Yoshinori Mitamura; Kunihiro Ishikawa; Masaru Inatani
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

9.  Circulating insulin-like growth factor-1: a new clue in the pathogenesis of age-related macular degeneration.

Authors:  Niccolò Castellino; Antonio Longo; Teresio Avitabile; Andrea Russo; Matteo Fallico; Vincenza Bonfiglio; Mario Damiano Toro; Robert Rejdak; Katarzyna Nowomiejska; Paolo Murabito; Claudio Furino; Michele Reibaldi
Journal:  Aging (Albany NY)       Date:  2018-12-29       Impact factor: 5.682

10.  Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach.

Authors:  Anne-Sofie Petri; Kirstine Boysen; Lasse J Cehofski; Elon H C van Dijk; Chantal Dysli; Josefine Fuchs; Rodolfo Mastropasqua; Yousif Subhi
Journal:  Ophthalmol Ther       Date:  2020-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.